Despite the rising competition in the obesity space, we believe that there is room for smaller biotechs like Viking Therapeutics to grab a share of this booming market.

Obesity rates in the United States have finally started to show a ... there is no guarantee the downward trend will continue. A graph representing the US adult population with obesity by race.

Americans are bombarded with headlines about the benefits of alcohol (“Wine may be good for the heart, new study says”).

Along with the warning that alcohol consumption can increase cancer risk, Surgeon General Dr. Vivek Murthy called for an ...

The U.S. surgeon general has urged updating the label on alcoholic drinks to cite the increased risk of cancer.

but not for long Eli Lilly is still slightly behind Novo Nordisk in terms of market share of the incretin class in obesity in the United States, but this is more a reflection of the inability of ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

Eli Lilly and Company’s LLY shares declined 13.5% in the past three months. Though demand for its popular tirzepatide drugs, ...

New Year’s is receding fast in the rearview mirror. And for many of us, our sincere resolutions about losing weight and ...

Chart showing Novo Nordisk's share ... but more complex to manufacture," he said. Lilly's own obesity injection - sold as Zepbound in the United States - led to an average weight loss of nearly ...

The drug and biotech industry had a tough time in the past couple of months after Trump announced the appointment of Robert F ...

Is your New Year’s resolution to cut back on alcohol? Dry January is here and Brevard County has plenty of mocktail options.